Here's how the ASX 200 market sectors stacked up last week

The worst-performing market sector of 2024 was the best performer in the first week of 2025.

Multiracial happy young people stacking hands outside - University students hugging in college campus - Youth community concept with guys and girls standing together supporting each other.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Energy stocks led the ASX 200 market sectors with a 4.56% gain in the new year's first week of trading.

Meantime, the S&P/ASX 200 Index (ASX: XJO) rose by 0.05% to finish the week at 8,250.5 points.

Six of the 11 market sectors finished the short trading week (due to the Wednesday New Year's Day holiday) in the green.

Let's review.

Energy shares led the ASX sectors last week

One wonders whether it was irony or inevitability that energy emerged as the strongest sector in week one of 2025 trading, given it was, by far, the worst-performing sector of 2024.

The energy index tumbled 18.83% last year amid geopolitical tensions, volatile commodities, and the increasingly concerning economic slowdown in China, which is the world's biggest importer of crude oil.

The energy sector's strong performance last week followed another challenging month for the sector.

The S&P/ASX 200 Energy Index (ASX: XEJ) fell to a 52-week low of 8,141.3 points on 19 December.

That appears to have been the turning point for investors, with the index rebounding 8.24% since then.

Last week, investors seemed to be reassessing the sector's new year prospects and seeking to capitalise on beaten-down stock prices amid new year optimism in the marketplace.

A bit of new strength in commodity prices also boosted the energy sector last week.

Brent crude oil futures rose to about US$76.10 per barrel on Friday, a near two-month high. It was the same story for WTI futures, which rose to about $73.40 per barrel, also a near two-month high.

Investors are hoping China's pledges of new stimulus last year, as well as interest rate cuts suggested by the People's Bank of China today, will boost the ailing economy.

A continued decline in US crude inventories provided further support to commodity prices last week.

Among the major ASX 200 oil shares, Woodside Energy Group Ltd (ASX: WDS) shares lifted 4.09% to $25.20 apiece. The Santos Ltd (ASX: STO) share price lifted 5.19% to $6.88.

Beach Energy Ltd (ASX: BPT) shares rose 5.13% to $1.44. Karoon Energy Ltd (ASX: KAR) shares ascended 10.81% to $1.44 apiece.

Ampol Ltd (ASX: ALD) shares rose 6.53% to $29.21. Viva Energy Group Ltd (ASX: VEA) shares gained 4.98% to $2.74.

ASX uranium shares also had a strong week, helped by a 2.19% boost to the uranium price in the new year.

The Deep Yellow Limited (ASX: DYL) share price shot 11.84% higher to close at $1.27 on Friday.

Boss Energy Ltd (ASX: BOE) shares weren't far behind, with a 10.5% gain over the four trading days to close at $2.61. The Paladin Energy Limited (ASX: PDN) share price lifted 7.95% to $8.23.

ASX 200 market sector snapshot

Here's how the 11 market sectors stacked up last week, according to CommSec data.

Over the four trading days:

S&P/ASX 200 market sectorChange last week
Energy (ASX: XEJ)4.56%
Materials (ASX: XMJ)0.22%
Healthcare (ASX: XHJ)0.17%
Utilities (ASX: XUJ)0.13%
Industrials (ASX: XNJ)0.02%
Communication (ASX: XTJ)0.01%
Information Technology (ASX: XIJ)(0.05%)
Consumer Staples (ASX: XSJ)(0.11%)
Financials (ASX: XFJ)(0.12%)
Consumer Discretionary (ASX: XDJ)(0.5%)
A-REIT (ASX: XPJ)(1.52%)

Motley Fool contributor Bronwyn Allen has positions in Woodside Energy Group. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Contented looking man leans back in his chair at his desk and smiles.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

Three small children reach up to hold a toy rocket high above their heads in a green field with a blue sky above them.
Growth Shares

These 4 ASX 200 stocks could jump another 70% to 80% in 2026

These stocks are expected to rocket higher.

Read more »

Two excited woman pointing out a bargain opportunity on a laptop.
Share Gainers

3 ASX 200 stocks jumping higher in this week's falling market

Investors shrugged off the broader market retrace and piled into these three ASX 200 stocks this week.

Read more »

A woman with a sad face looks to be receiving bad news on her phone as she holds it in her hands and looks down at it.
Share Fallers

Why EOS, Lotus Resources, REA, and Web Travel shares are dropping today

These shares are ending the week deep in the red. But why?

Read more »

A businessman looking at his digital tablet or strategy planning in hotel conference lobby. He is happy at achieving financial goals.
Share Gainers

Why Brambles, HMC Capital, ResMed, and Rio Tinto shares are rising today

These shares are avoiding the selloff and are pushing higher on Friday.

Read more »

A woman looks shocked as she drinks a coffee while reading the paper.
Share Fallers

Why is the Web Travel share price crashing 41% on Friday?

ASX investors are pummelling Web Travel shares today. But why?

Read more »

A man looking at his laptop and thinking.
Materials Shares

Rio Tinto shares charge higher after Glencore merger collapses

The parties couldn't come to an agreement.

Read more »

a group of doctors and medical staff in uniform high five in celebration in a hospital setting
Share Market News

Neuren Pharmaceuticals kicks off Phase 3 trial in rare syndrome

Neuren Pharmaceuticals shares are on watch after dosing began in its key Phase 3 trial for Phelan-McDermid syndrome.

Read more »